HopeStage
Back to all studies
RecruitingNCT06504290

VV119 dose and safety study in healthy adults and adults with schizophrenia

About this titleRead the official source — NCT06504290
Medication studyAges 18–65China
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

What will I do during this study?

The study has two parts: healthy adults receive daily oral VV119 or placebo (an inactive comparison treatment) for 14 days; adults with schizophrenia receive dose-escalating VV119 or placebo for up to 28 days.

Listed locations
Beijing and 3 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: July 16, 2024
Recruitment status
Recruiting
Enrollment listed in the registry
40
Sponsor
Vigonvita Life Sciences
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
China
Age range
From 18 Years to 65 Years
Official registry ID
NCT06504290
Official title
Show the full official title

A Phase I Clinical Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VV119 Capsules With Multiple Ascending Doses in Chinese Healthy Adult Subjects and Patients With Schizophrenia

Recruitment & locations

Currently recruiting

Beijing · Xi’an

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Vigonvita Life Sciences.

Does this study involve medication?

Yes. The study involves medication, including VV119 Placebo and VV119.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies